Tag: USPTO

At the heart of a patent application lies its claims. A claim is a signifier of the scope of protection that is sought under the patent. Claims are the first and most important aspect to be examined during prosecution, infringement, and litigation. Every patent application must be accompanied by at least one claim, and usually, an application contains several more. ......

The phrase “at least one of” is commonly used in patent claims, but its interpretation is subjective and has led to some controversy. The issue that arises is this: when the phrase in its entirety is “at least one of A, B and C”, should it be understood as at least one of A AND at least one of B AND at least one of C, or should it be understood as at least one of A OR B OR C. ......

Besides the patentability requirements of novelty, inventive step, and being capable of industrial applicability, a patent application must also meet the enablement requirement in order to be granted. A patent application is said to be enabled if the application provides sufficient details that enable a person of ordinary skill in the related field to practice the invention. ......

On April 22, 2020, the United States Patent and Trademarks Office (the “USPTO”) issued an order  refusing inventorship of a patent application to DABUS, an Artificial Intelligence (AI) machine. This decision, which broadly appears to align with the position being taken in Europe and the United Kingdom with regard to the same invention, is likely to have a significant impact on the future of patenting, at least until there are statutory amendments to the contrary, or until it gets overturned for any reason....

On 16 January 2020, the European Patent Office (EPO) Board of Appeal revoked a patent related to CRISPR/Cas9 technology, and in doing so delivered one of the most anticipated decisions in the field of biotechnology patents in recent times. This gene-editing technology, which is the subject of a bitter battle for intellectual property rights between two rival parties - The Broad Institute and the University of California (UC), Berkeley, is revolutionizing research in biotechnology....

Artificial Intelligence (AI) is changing the way we live and engage with the world. Besides smart devices (phones, speakers), and self-driving cars, AI is also set to revolutionize biotechnology and the health sector. Deep learning algorithms are being used in areas such as genomic data analysis, cellular profiling and characterisation which find use, for example, in cancer diagnosis, drug design and pharmacology, genome sequencing, and protein structure prediction. ...

Over the years, a large number of patents have been granted for antibodies all over the world. The world is also seeing a shift towards biologic based drugs. Most of the top-selling drugs in 2018 were monoclonal antibodies with HUMIRA® leading the list. With the progress in the art and growing case law in this area, the criteria for patentability of antibodies are becoming increasingly strict, with restrictions on the scope of the claims. ...